【摘要】 目的探讨急性心肌梗死患者急诊经皮冠状动脉介入治疗(PCI)中应用比伐芦定30 d时的临床疗效。方法选择2012年2—7月收治的58例12 h内出现症状、均接受急诊PCI的急性心肌梗死患者为研究对象,其中30例在PCI实施前应用比伐芦定,28例接受普通肝素。观察并比较两组患者的冠状动脉病变特征、PCI指标及30 d临床事件发生率。结果两组患者的介入治疗路径、TIMI血流、病变支数间差异均无统计学意义(P>0.05),两组手动血栓抽吸装置和替罗非班使用率间差异有统计学意义(P<0.05)。两组患者随访30 d均无死亡、支架内血栓、再发心肌梗死发生。两组30 d心力衰竭、因心绞痛再次住院率及不良反应发生率比较,差异均无统计学意义(P>0.05)。普通肝素组发生严重出血1例,比伐卢定组无大出血发生。结论在急性心肌梗死患者急诊PCI中应用比伐卢定具有较好的临床效果和安全性。更多还原

【Abstract】 Objective To evaluate the 30-day efficacy of bivalirudin in patients with acute myocardial infarction(AMI) who underwent emergency PCI.Methods Fifty-eight AMI patients admitted from February to July 2012 had symptoms and received emergency PCI,thereinto 30 patients had bivalirudin before PCI,28 had unfractioned heparin(UFH).Results No significant difference was noted in interventional treatment path,TIMI blood flow,number of diseased vessels between 2 groups(P>0.05),but there was in utilization ratio of manual thrombus suction device and tirofiban(P<0.05).No deaths,stent thrombosis or recurrent myocardial infarction occurred during 30-day follow-up.There was not difference in re-hospitalization rate,incidence of heart failure or other adverse reaction between 2 groups(P>0.05).In UFH group 1 had severe bleeding,but in bivalirudin group no one had.Conclusion Using bivalirudin in emergency PCI is of good safety in AMI patients.更多还原